Dr. Long currently leads the Biology team at ROME Therapeutics and is working to develop novel therapeutics targeting the Dark Genome for the treatment of autoimmune disorders. Dr Long has extensive experience in the development of therapeutics across a broad range of therapeutic areas, including musculoskeletal and neuromuscular disorders, metabolic dysfunction, and inflammatory disorders. Dr. Long most recently was the Head of Biology at Casma Therapeutics, where she and her team worked to develop and characterize novel autophagy-based degraders for use in multiple therapeutic areas. She has also held multiple positions at Scholar Rock, where she was closely involved with development of the anti-proMyostatin antibody apitegromab, and where she led the efforts of the exploratory biology team. Dr. Long also held positions at Ironwood Pharmaceuticals and Pfizer. Dr. Long received a B.A. in molecular and cellular biology from Northwestern University and a Ph.D. in Biological Sciences from Stanford University.
